A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
about
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaRedox-directed cancer therapeutics: molecular mechanisms and opportunitiesPotential therapeutic approaches for modulating expression and accumulation of defective lamin A in laminopathies and age-related diseasesMulticenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma.Arsenic trioxide - An old drug rediscovered.The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsA copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo.Arsenic Trioxide Combined with VCMP or VAD Chemotherapy in Patients with Refractory or Relapsed Multiple Myeloma in a Single Institution of ChinaAntimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.Proteasome inhibitors in the treatment of multiple myelomaIntravenous Vitamin C and Cancer: A Systematic Review.The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention.Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma.Arsenic trioxide inhibits the proliferation of myeloma cell line through notch signaling pathway.A combination of two antioxidants (an SOD mimic and ascorbate) produces a pro-oxidative effect forcing Escherichia coli to adapt via induction of oxyR regulon.From the bench to the bedside: emerging new treatments in multiple myeloma.Bortezomib in the front-line treatment of multiple myeloma.Treatment of relapsed and refractory myeloma.Appetite for destruction: E3 ubiquitin-ligase protection in cardiac disease.Pathogenesis and treatment of leukemia: an Asian perspective.Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review.Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways.Mitochondrial ascorbic acid is responsible for enhanced susceptibility of U937 cells to the toxic effects of peroxynitrite.Anticancer activity in human multiple myeloma U266 cells: synergy between cryptotanshinone and arsenic trioxide.As(2)O (3) oxidation by vitamin C: cell culture studies.A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.Network-based analysis of the molecular mechanisms of multiple myeloma and monoclonal gammopathy of undetermined significance.Challenging issues in molecular-targeted therapy.Arsenic trioxide increases expression of secreted frizzled-related protein 1 gene and inhibits the WNT/β-catenin signaling pathway in Jurkat cells.A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.TP53 alteration determines the combinational cytotoxic effect of doxorubicin and an antioxidant NAC.Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.Bortezomib/bendamustine/dexamethasone induced good PR in refractory relapse post auto-SCT with constitutive RAS activation due to V600E BRAF mutation.Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA).Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side.153Sm: its use in multiple myeloma and report of a clinical experienceEmergence of Members of TRAF and DUB of Ubiquitin Proteasome System in the Regulation of Hypertrophic Cardiomyopathy
P2860
Q24605527-5221AC02-7286-44DF-BF96-A1DEAE3B3C08Q24645584-E8E2C83A-9F7D-41F8-91F7-70E3623B9C9FQ28391383-7CE2ADD9-DB28-4580-BC1F-B9FFDCF65617Q33386405-99227A8F-5A28-47A5-A650-9EF71CFF30EBQ33397376-8E9CF1BF-EEDB-45C3-B7A4-FC83A250BC1EQ34054167-E84419BF-A0F9-422D-9AA2-6F3DBD991EC9Q34218976-0C9F7707-6851-42C0-B568-4A3E02BDC1E8Q34459006-3AE1C78E-6F9B-4CAE-87B3-CE1B14689DB6Q34569038-B38D7EDE-F097-4D37-B6CD-DA0EAEC37BFBQ34580540-4EA6BE9A-BFD2-424A-9693-547DBC49BF15Q34611676-0AB5732C-CF3A-4413-8CE5-FF7103467F65Q35175163-08329450-B661-4DE1-A2A1-4155266AAD1FQ35836872-35339740-060C-45C4-8F7D-F0EB391719ECQ35836881-CCB3DAA0-68D3-4991-A84A-921E322AAC1DQ36658048-87E0576C-F1CB-42F7-A348-C744450A499EQ36693641-E96950D0-B4BF-40E3-8120-645586504F7DQ36839447-E021B609-7685-480F-8A8E-05B319612271Q37028598-2A9C48CB-F420-4DD4-A625-FA374A59D835Q37202761-0DB41161-F8CC-4469-AF01-E993D76D7EFDQ37209929-2FAA5760-1A66-4708-854A-A964FFBEA39EQ37526448-C992A677-FD94-48F4-A314-E1C6B8C5AA07Q37982115-B4D3A118-2AE5-4E68-8B1E-E98AD2750DEBQ38253354-7B2B3AC2-4A3A-4F4B-AE79-BCB558B23FA1Q38676278-C6F78D70-6877-403A-A0D8-C03C286C97C2Q39084320-E0362520-7C14-48B4-AC8E-AE595CAFFB91Q39175673-559DA17B-5C55-415D-A89E-6288B3B4CDDEQ39493615-267F23C7-FAC5-44E5-BAF6-C0D9662308BDQ41385777-E80AABCC-2B03-4528-9CFA-4866CDF0B1E1Q41390701-C4C1DFA9-8AD8-43E0-8F90-910B59F3092BQ41436013-8821F88B-DB5C-4693-95F5-AF5D14394C86Q41788771-5B710878-356B-4E18-8826-E0E17AB7F795Q45342587-BF22317F-0BBB-484F-AF83-54CD4A3AE246Q46343999-999DC6AC-311E-472E-B920-A9FAB0F9FCA2Q47630577-9912213C-BCC9-490F-AEB8-56774E7395E0Q49244147-C26B0500-23AD-442D-8A1E-46426570C937Q54329197-DDCA7F9F-7A92-4183-9CD4-4B86C023E86DQ55451692-FEBB06EB-7666-4B53-8EC6-CA71C851C75DQ55503143-DE83D4AB-4F1A-446B-9F7F-21F151FA681CQ58449064-3A4DC94A-97AE-4799-8F28-792E49CFEB2AQ58728912-1794AE2E-887C-4EE9-9E30-D055DE59B611
P2860
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A phase I/II study of arsenic ...... r refractory multiple myeloma.
@ast
A phase I/II study of arsenic ...... r refractory multiple myeloma.
@en
type
label
A phase I/II study of arsenic ...... r refractory multiple myeloma.
@ast
A phase I/II study of arsenic ...... r refractory multiple myeloma.
@en
prefLabel
A phase I/II study of arsenic ...... r refractory multiple myeloma.
@ast
A phase I/II study of arsenic ...... r refractory multiple myeloma.
@en
P2093
P1476
A phase I/II study of arsenic ...... r refractory multiple myeloma.
@en
P2093
Blake Morrison
Howard S Yeh
James R Berenson
Jeffrey Matous
Regina A Swift
Russell Mapes
P304
P356
10.1158/1078-0432.CCR-06-1812
P407
P577
2007-03-01T00:00:00Z